Oxide overlayer formation on sputtered ScAlN film exposed to air von Li, Minghua, Lin, Huamao, Hu, Kan, Zhu, Yao

Volltext

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial von Camidge, D Ross, Kim, Hye Ryun, Ahn, Myung-Ju, Yang, James C H, Han, Ji-Youn, Hochmair, Maximilian J, Lee, Ki Hyeong, Delmonte, Angelo, García Campelo, Maria Rosario, Kim, Dong-Wan, Griesinger, Frank, Felip, Enriqueta, Califano, Raffaele, Spira, Alexander, Gettinger, Scott N, Tiseo, Marcello, Lin, Huamao M, Gupta, Neeraj, Hanley, Michael J, Ni, Quanhong, Zhang, Pingkuan, Popat, Sanjay

Volltext

Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial von Camidge, D. Ross, Kim, Hye Ryun, Ahn, Myung-Ju, Yang, James C.H., Han, Ji-Youn, Hochmair, Maximilian J., Lee, Ki Hyeong, Delmonte, Angelo, Garcia Campelo, Maria Rosario, Kim, Dong-Wan, Griesinger, Frank, Felip, Enriqueta, Califano, Raffaele, Spira, Alexander I., Gettinger, Scott N., Tiseo, Marcello, Lin, Huamao M., Liu, Yuyin, Vranceanu, Florin, Niu, Huifeng, Zhang, Pingkuan, Popat, Sanjay

Volltext

Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non–Small-Cell Lung Cancer von Jahanzeb, Mohammad, Lin, Huamao M., Pan, Xiaoyun, Yin, Yu, Baumann, Pia, Langer, Corey J.

Volltext

Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC von Ou, Sai-Hong Ignatius, Hong, Jin-Liern, Christopoulos, Petros, Lin, Huamao M., Vincent, Sylvie, Churchill, Eric N., Soeda, Junpei, Kazdal, Daniel, Stenzinger, Albrecht, Thomas, Michael

Volltext

Establishing Meaningful Change Thresholds in Patient-Reported Outcomes Among Patients With Anaplastic Lymphoma Kinase-Positive Non–Small Cell Lung Cancer in ALTA-1L Trial von Beaumont, Jennifer L., Lin, Huamao M., Goodman, Erin, Yu, Hailin, Geiger, Ashley, Hudgens, Stacie

Volltext

Real‐World Treatment Patterns and Progression‐Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non‐Small Cell Lung Cancer... von Jahanzeb, Mohammad, Lin, Huamao M., Pan, Xiaoyun, Yin, Yu, Wu, Yanyu, Nordstrom, Beth, Socinski, Mark A.

Volltext

Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC von Arnaoutakis, Konstantinos, Wan, Yin, Elliott, Jennifer, Young, Matt, Yin, Yu, Leventakos, Konstantinos, Lin, Huamao M., Dimou, Anastasios

Volltext

Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Rea... von Parikh, Kaushal, Dimou, Anastasios, Leventakos, Konstantinos, Mansfield, Aaron S., Shanshal, Mohamed, Wan, Yin, Lin, Huamao M., Vincent, Sylvie, Elliott, Jennifer, Bonta, Ioana R.

Volltext

Economic burden in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with or without brain metastases, receiving first-line ALK inhibitors von Wu, Yanyu, Ren, Kaili, Wan, Yin, Lin, Huamao M

Volltext

Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial von Yang, James Chih-Hsin, Liu, Geoffrey, Lu, Shun, He, Jianxing, Burotto, Mauricio, Ahn, Myung-Ju, Kim, Dong-Wan, Liu, XiaoQing, Zhao, Yanqiu, Vincent, Sylvie, Yin, Jiani, Ma, Xin, Lin, Huamao M, Popat, Sanjay

Volltext

Flexible thin-film acoustic wave devices with off-axis bending characteristics for multisensing applications von Ji, Zhangbin, Zhou, Jian, Lin, Huamao, Wu, Jianhui, Zhang, Dinghong, Garner, Sean, Gu, Alex, Dong, Shurong, Fu, YongQing, Duan, Huigao

Volltext

Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States von Jahanzeb, Mohammad, Lin, Huamao M, Wu, Yanyu, Zhang, Pingkuan, Gorritz, Magdaliz, McGuiness, Catherine B, Huang, Wei-Ti, Sun, Kainan, Chen, Chi-Chang, Camidge, D. Ross

Volltext

Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2) von Ou, Sai-Hong Ignatius, Nishio, Makoto, Ahn, Myung-Ju, Mok, Tony, Barlesi, Fabrice, Zhou, Caicun, Felip, Enriqueta, de Marinis, Filippo, Kim, Sang-We, Pérol, Maurice, Liu, Geoffrey, Migliorino, Maria Rita, Kim, Dong-Wan, Novello, Silvia, Bearz, Alessandra, Garrido, Pilar, Mazieres, Julien, Morabito, Alessandro, Lin, Huamao M., Yang, Hui, Niu, Huifeng, Zhang, Pingkuan, Kim, Edward S.

Volltext

Response to “NGS, the New Global Standard?” von Ou, Sai-Hong Ignatius, Hong, Jin-Liern, Christopoulos, Petros, Lin, Huamao M., Vincent, Sylvie, Churchill, Eric N., Soeda, Junpei, Kazdal, Daniel, Thomas, Michael, Stenzinger, Albrecht

Volltext

Identifying symptomatic adverse events using the patient‐reported outcomes version of the common terminology criteria for adverse events in patients with non‐small cell lung cancer... von Zhu, Yanyan, Jean‐Baptiste, Milenka, Lenderking, William R., Bell, Jill A., Revicki, Dennis A., Lin, Huamao M., Brake, Rachael, Reeve, Bryce B.

Volltext

The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions von Christopoulos, Petros, Kluck, Klaus, Kirchner, Martina, Lüders, Heike, Roeper, Julia, Falkenstern-Ge, Roger-Fei, Szewczyk, Marlen, Sticht, Florian, Saalfeld, Felix C., Wesseler, Claas, Hackanson, Björn, Dintner, Sebastian, Faehling, Martin, Kuon, Jonas, Janning, Melanie, Kauffmann-Guerrero, Diego, Kazdal, Daniel, Kurz, Sylke, Eichhorn, Florian, Bozorgmehr, Farastuk, Shah, Rajiv, Tufman, Amanda, Wermke, Martin, Loges, Sonja, Brueckl, Wolfgang M., Schulz, Christian, Misch, Daniel, Frost, Nikolaj, Kollmeier, Jens, Reck, Martin, Griesinger, Frank, Grohé, Christian, Hong, Jin-Liern, Lin, Huamao M., Budczies, Jan, Stenzinger, Albrecht, Thomas, Michael

Volltext

Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program von Lin, Huamao M, Pan, Xiaoyun, Hou, Peijie, Allen, Susan, Baumann, Pia, Hochmair, Maximilian J

Volltext

A Low Temperature Drifting Acoustic Wave Pressure Sensor with an Integrated Vacuum Cavity for Absolute Pressure Sensing von Wang, Tao, Tang, Zhengjie, Lin, Huamao, Zhan, Kun, Wan, Jiang, Wu, Shihao, Gu, Yuandong, Luo, Wenbo, Zhang, Wanli

Volltext

Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor–naive ALK + non−small cell lung cancer (ALTA-1L) von Garcia Campelo, Maria Rosario, Lin, Huamao M., Zhu, Yanyan, Pérol, Maurice, Jahanzeb, Mohammad, Popat, Sanjay, Zhang, Pingkuan, Camidge, D. Ross

Volltext